PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression.

Abstract This study aimed to investigate prospective memory impairment in patients with breast cancer with different expression of hormone receptors, including the estrogen receptor (ER) and the progesterone receptor (PR).A total of 120 patients with breast cancer who underwent chemotherapy following surgery were divided into 2 groups. The A group included 60 patients with ER/PR status, and the B group included 60 patients with ER/PR status. After 6 cycles of postoperative adjuvant chemotherapy, all patients were administered neuropsychological and prospective memory tests, such as the Mini-Mental State Examination (MMSE), verbal fluency test (VFT), and digit span test (DST), as well as examination of event-based prospective memory (EBPM) and time-based prospective memory (TBPM).As the neuropsychological background test results showed, there were no significant differences in MMSE, DST, and TBPM scores (*:P > 0.05) between patients with breast cancer in the ER/PR and ER/PR groups, while the VFT and EBPM scores were significantly greater in patients with breast cancer with ER/PR status than in those with ER/PR status (**: P < 0.01), indicating that patients with ER/PR status have significant impairment in EBPM, although not in TBPM.The results of the present study indicate that different hormone receptor expression in patients with breast cancer may be associated with heterogeneity of chemotherapy-induced prospective memory impairment.
PMID
Related Publications

Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.

Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.

Impact of metastatic estrogen receptor and progesterone receptor status on survival.

Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.

Chemotherapy-induced prospective memory impairment in patients with breast cancer.

Authors

Mayor MeshTerms

Memory, Episodic

Keywords
Journal Title medicine
Publication Year Start




PMID- 28353608
OWN - NLM
STAT- MEDLINE
DA  - 20170329
DCOM- 20170406
LR  - 20170406
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 13
DP  - 2017 Mar
TI  - Chemotherapy-induced prospective memory impairment in breast cancer patients with
      different hormone receptor expression.
PG  - e6514
LID - 10.1097/MD.0000000000006514 [doi]
AB  - This study aimed to investigate prospective memory impairment in patients with
      breast cancer with different expression of hormone receptors, including the
      estrogen receptor (ER) and the progesterone receptor (PR).A total of 120 patients
      with breast cancer who underwent chemotherapy following surgery were divided into
      2 groups. The A group included 60 patients with ER/PR status, and the B group
      included 60 patients with ER/PR status. After 6 cycles of postoperative adjuvant 
      chemotherapy, all patients were administered neuropsychological and prospective
      memory tests, such as the Mini-Mental State Examination (MMSE), verbal fluency
      test (VFT), and digit span test (DST), as well as examination of event-based
      prospective memory (EBPM) and time-based prospective memory (TBPM).As the
      neuropsychological background test results showed, there were no significant
      differences in MMSE, DST, and TBPM scores (*:P &gt; 0.05) between patients with
      breast cancer in the ER/PR and ER/PR groups, while the VFT and EBPM scores were
      significantly greater in patients with breast cancer with ER/PR status than in
      those with ER/PR status (**: P &lt; 0.01), indicating that patients with ER/PR
      status have significant impairment in EBPM, although not in TBPM.The results of
      the present study indicate that different hormone receptor expression in patients
      with breast cancer may be associated with heterogeneity of chemotherapy-induced
      prospective memory impairment.
FAU - Li, Wen
AU  - Li W
AD  - Department of Oncology, The Second Affiliated Hospital of Anhui Medical
      University, Hefei, Anhui, China.
FAU - Gan, Chen
AU  - Gan C
FAU - Lv, Yue
AU  - Lv Y
FAU - Wang, Shanghu
AU  - Wang S
FAU - Cheng, Huaidong
AU  - Cheng H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/*adverse effects
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Carcinoma/*drug therapy/metabolism
MH  - Female
MH  - Humans
MH  - Memory Disorders/*chemically induced
MH  - *Memory, Episodic
MH  - Middle Aged
MH  - Psychometrics
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
EDAT- 2017/03/30 06:00
MHDA- 2017/04/07 06:00
CRDT- 2017/03/30 06:00
AID - 10.1097/MD.0000000000006514 [doi]
AID - 00005792-201703310-00054 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Mar;96(13):e6514. doi: 10.1097/MD.0000000000006514.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>